Anebulo Pharmaceuticals (ANEB) Competitors $3.19 -0.05 (-1.54%) Closing price 04:00 PM EasternExtended Trading$3.20 +0.00 (+0.16%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. MNPR, MREO, KOD, ZYBT, TVRD, INZY, AARD, ACB, NBTX, and PRQRShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Monopar Therapeutics (MNPR), Mereo BioPharma Group (MREO), Kodiak Sciences (KOD), Zhengye Biotechnology (ZYBT), Tvardi Therapeutics (TVRD), Inozyme Pharma (INZY), Aardvark Therapeutics (AARD), Aurora Cannabis (ACB), Nanobiotix (NBTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Its Competitors Monopar Therapeutics Mereo BioPharma Group Kodiak Sciences Zhengye Biotechnology Tvardi Therapeutics Inozyme Pharma Aardvark Therapeutics Aurora Cannabis Nanobiotix ProQR Therapeutics Monopar Therapeutics (NASDAQ:MNPR) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Do analysts rate MNPR or ANEB? Monopar Therapeutics currently has a consensus price target of $60.00, indicating a potential upside of 33.42%. Anebulo Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 72.41%. Given Anebulo Pharmaceuticals' higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Anebulo Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is MNPR or ANEB more profitable? Monopar Therapeutics' return on equity of -55.39% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Monopar TherapeuticsN/A -55.39% -51.53% Anebulo Pharmaceuticals N/A -90.11%-84.53% Does the media prefer MNPR or ANEB? In the previous week, Anebulo Pharmaceuticals had 8 more articles in the media than Monopar Therapeutics. MarketBeat recorded 10 mentions for Anebulo Pharmaceuticals and 2 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.07 beat Anebulo Pharmaceuticals' score of 0.53 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anebulo Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of MNPR or ANEB? 1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, MNPR or ANEB? Monopar Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonopar TherapeuticsN/AN/A-$15.59M-$3.48-12.92Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-12.27 Which has more volatility & risk, MNPR or ANEB? Monopar Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the S&P 500. SummaryAnebulo Pharmaceuticals beats Monopar Therapeutics on 7 of the 13 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$133.12M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-12.278.6721.1920.14Price / SalesN/A328.69461.30104.37Price / CashN/A42.7636.2258.56Price / Book21.278.378.665.87Net Income-$8.20M-$55.19M$3.25B$258.55M7 Day Performance94.51%5.89%4.20%2.23%1 Month Performance117.01%17.63%10.82%12.76%1 Year Performance45.00%5.09%34.70%19.36% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.0905 of 5 stars$3.19-1.5%$5.50+72.4%+35.0%$133.12MN/A-12.274News CoverageAnalyst ForecastMNPRMonopar Therapeutics2.2868 of 5 stars$43.53-0.5%$60.00+37.8%+1,363.1%$267.35MN/A-12.5510Positive NewsMREOMereo BioPharma Group1.7907 of 5 stars$1.66-3.8%$7.20+335.0%-55.9%$263.15M$10M-23.6440KODKodiak Sciences2.5305 of 5 stars$4.95-4.4%$9.00+82.0%+173.2%$261.22MN/A-1.3690ZYBTZhengye BiotechnologyN/A$5.49-6.5%N/AN/A$258.94M$186.36M0.00278Positive NewsGap UpTVRDTvardi TherapeuticsN/A$27.60-7.5%$64.25+132.8%N/A$258.34M$7.14M0.0080INZYInozyme Pharma2.7992 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750AARDAardvark TherapeuticsN/A$11.64-3.9%$33.00+183.5%N/A$252.54MN/A0.0018ACBAurora Cannabis0.2778 of 5 stars$4.48-2.3%N/A-16.5%$251.54M$246.72M40.681,130NBTXNanobiotix1.6198 of 5 stars$5.33+3.4%$8.00+50.2%+22.0%$251.01M$39.18M0.00100News CoverageGap UpPRQRProQR Therapeutics2.8831 of 5 stars$2.38-4.2%$8.00+236.8%+20.2%$249.87M$20.46M-6.79180 Related Companies and Tools Related Companies Monopar Therapeutics Alternatives Mereo BioPharma Group Alternatives Kodiak Sciences Alternatives Zhengye Biotechnology Alternatives Tvardi Therapeutics Alternatives Inozyme Pharma Alternatives Aardvark Therapeutics Alternatives Aurora Cannabis Alternatives Nanobiotix Alternatives ProQR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANEB Stock Alerts